EuroNanoMed NanoBiT: Nanoscintillator-Porphyrin Complexes for Bimodal RadioPhotoDynamic Therapy
Project duration 2016-2019
Funding Agencies: ERA-NET EuroNanoMed II and the Research Council's of Norway NANO2021 programme
Project number: 258074
Status: Kick-off in 2016
Partners:
Dr. Petras Juzenas, Radiumhospitalet, Oslo University Hospital, Oslo, Norway (coordinator)
Prof. Céline Frochot, French National Centre for Scientific Research (CNRS), Nancy, France
Prof. Milos Nesladek, Universiteit Hasselt, Hasselt, France
Prof. Thierry Bastogne, CYBERnano, Nancy, France
Dr. Benoit Habermeyer, PorphyChem, Dijon, France
Funding Agencies: ERA-NET EuroNanoMed II and the Research Council's of Norway NANO2021 programme
Project number: 258074
Status: Kick-off in 2016
Partners:
Dr. Petras Juzenas, Radiumhospitalet, Oslo University Hospital, Oslo, Norway (coordinator)
Prof. Céline Frochot, French National Centre for Scientific Research (CNRS), Nancy, France
Prof. Milos Nesladek, Universiteit Hasselt, Hasselt, France
Prof. Thierry Bastogne, CYBERnano, Nancy, France
Dr. Benoit Habermeyer, PorphyChem, Dijon, France
Clinical benefits of currently available radiosensitizers are highly debated. Here nanotechnology gives promising possibilities for the purposes of this project due to i) relatively easy synthesis procedures and versatile user-tailored tuning capabilities of nanomaterials, and ii) our suggested nanoparticles are most suitable photocatalysts (radiocatalysts) because organic molecules do not possess such feature. Our hypothesis is that cancer cells can be selectively marked and sensitized to radiation by nanoparticles through increased amount of intracellularly generated free radicals and reactive oxygen species. Since radiation is used in about half of cancer treatment cases the project results may have a significant clinical impact.
